Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2403

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2403
---
 Statement”).

As
of the close of business on September 20, 2024, the record date for the Annual Meeting, 5,766,704 shares of the Company’s
common stock, par value $0.0001 per share (“Common Stock”), were issued, outstanding and entitled to vote. Holders
of shares of Common Stock were entitled to one vote per share for each share of Common Stock. Stockholders holding an aggregate
of 3,950,312 votes were present at the Annual Meeting, in person or represented by proxy, which number constituted a quorum.

85 

Proposal
1 – The five (5) nominees named in the Proxy Statement were elected at the Annual Meeting to serve as the Company’s
directors until the Company’s 2025 Annual Meeting of Stockholders and until each of their respective successors are elected
and qualified or until each of their earlier resignation or removal. The final voting results with respect to the election of
each such nominee were as follows:

    Nominee
     
    For
     
    Withheld

    Todd Davis
     
    3,534,258
     
    815

    Ezra Friedberg
     
    3,534,258
     
    815

    Francis Knuettel II
     
    3,534,258
     
    815

    Dr. Richard Malamut
     
    3,534,254
     
    819

    Chia-Lin Simmons
     
    3,532,834
     
    2,239

There
were 415,239 broker non-votes with respect to each such nominee for the first proposal.

Proposal
2 – The amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares authorized
for issuance thereunder was approved by the Company’s stockholders. The final voting results were as follows:

    For
     
    Against
     
    Abstain

    3,527,889
     
    4,985
     
    2,199

There
were 415,239 broker non-votes with respect to the second proposal.

Proposal
3 – The proposal to waive the limit on the number of shares of Common Stock that may be issued to certain shareholders
pursuant to that certain Securities Purchase Agreement, dated July 24, 2024, and that certain Common